SBC hails ‘virtual scientists’ in novel AI partnership to speed biotech innovation

The collaboration introduces ‘virtual scientists’ to the SBC community, giving resident companies access to advanced AI tools that can automate time-consuming R&D tasks and help biotechs move from concept to discovery faster.

The alliance marks a milestone for Stevenage Bioscience Catalyst, which becomes the first UK science park to formally partner with an AI company in drug discovery. Together, SBC and Kiin Bio share a vision to make AI more accessible to early-stage innovators, supporting researchers and startups to apply AI across drug discovery, bioinformatics and competitive intelligence.

All companies based at SBC will receive a three-month pilot of the KiinOS platform, which includes access to three ‘virtual scientists’. The platform can perform and connect insights across a wide range of R & D tasks, from literature and biological searches to full bioinformatics (BIX) and cheminformatics (CIX) workflows, as well as competitor and landscape analyses.

“Partnering with Kiin Bio marks an important milestone for Stevenage Bioscience Catalyst as we continue to prepare our community for the AI era,” said Marco Delise, Director of Business Development and Entrepreneurship at SBC.

“By giving our companies access to Kiin’s virtual scientists and expertise, we’re helping biotechs embrace AI to speed up a variety of R&D processes, enabling them to save time and focus on what’s really important.”

Kiin Bio and SBC aim to set a new standard for how science parks can accelerate AI adoption, helping researchers, startups and emerging biotechs turn complex data into actionable discovery faster than ever before.

• Contact marco.delise@stevenagecatalyst.com to find out how SBC can support your company, from rent-free lab and office space to connections with industry partners such as GSK and LifeArc.